173 related articles for article (PubMed ID: 7828168)
1. Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine.
Risin D; Kleinerman ES; Umezu Y; Pizzini RP; Balch CM; Pellis NR
Cancer Immunol Immunother; 1995 Jan; 40(1):57-64. PubMed ID: 7828168
[TBL] [Abstract][Full Text] [Related]
2. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
Maeda M; Knowles RD; Kleinerman ES
Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
[TBL] [Abstract][Full Text] [Related]
3. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid).
Fujimaki W; Itoh K; An T; Gano JB; Ross MI; Mansfield PF; Balch CM; Augustus LB; Karkevitch DD; Johnston D
Cancer Biother; 1993; 8(4):307-18. PubMed ID: 7804372
[TBL] [Abstract][Full Text] [Related]
4. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
[TBL] [Abstract][Full Text] [Related]
6. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
[TBL] [Abstract][Full Text] [Related]
7. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.
Asano T; Matsushima K; Kleinerman ES
Cancer Immunol Immunother; 1994 Jan; 38(1):16-22. PubMed ID: 8299114
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide.
Landmann R; Obrist R; Denz H; Ludwig C; Frost H; Wesp M; Rordorf C; Towbin H; Gygax D; Tarcsay L
Biotherapy; 1993; 7(1):1-12. PubMed ID: 8068481
[TBL] [Abstract][Full Text] [Related]
9. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.
Maeda M; Asano T; Kleinerman ES
Cancer Immunol Immunother; 1993 Aug; 37(3):203-8. PubMed ID: 8334682
[TBL] [Abstract][Full Text] [Related]
10. Induction of serum tumor necrosis factor-alpha and interleukin-6 activity by liposome-encapsulated muramyl tripeptide-phosphatidylethanolamine (L-MTP-PE) in normal cats.
Fox LE; King RR; Shi F; Kurzman ID; MacEwen EG; Kubilis PS
Cancer Biother; 1994; 9(4):329-40. PubMed ID: 7719380
[TBL] [Abstract][Full Text] [Related]
11. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
Fujimaki W; Griffin JR; Kleinerman ES
Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
[TBL] [Abstract][Full Text] [Related]
12. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma.
Teske E; Rutteman GR; vd Ingh TS; van Noort R; Misdorp W
Anticancer Res; 1998; 18(2A):1015-9. PubMed ID: 9615757
[TBL] [Abstract][Full Text] [Related]
13. Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens.
Ullrich SE; Fidler IJ
J Leukoc Biol; 1992 Nov; 52(5):489-94. PubMed ID: 1431559
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
[TBL] [Abstract][Full Text] [Related]
15. [L-MTP-PE--a potential antineoplastic agent].
Dzierzbicka K; Gozdowska M; Kołodziejczyk AM
Postepy Hig Med Dosw; 1997; 51(2):227-36. PubMed ID: 9235567
[TBL] [Abstract][Full Text] [Related]
16. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
Pahl JH; Kwappenberg KM; Varypataki EM; Santos SJ; Kuijjer ML; Mohamed S; Wijnen JT; van Tol MJ; Cleton-Jansen AM; Egeler RM; Jiskoot W; Lankester AC; Schilham MW
J Exp Clin Cancer Res; 2014 Mar; 33(1):27. PubMed ID: 24612598
[TBL] [Abstract][Full Text] [Related]
17. Regional muramyl tripeptide phosphatidylethanolamine administration enhances hepatic immune function and tumor surveillance.
Karpoff HM; Jarnagin W; Delman K; Fong Y
Surgery; 2000 Aug; 128(2):213-8. PubMed ID: 10922994
[TBL] [Abstract][Full Text] [Related]
18. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
Tandon P; Utsugi T; Sone S
Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
[TBL] [Abstract][Full Text] [Related]
19. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
Fogler WE; Fidler IJ
Int J Immunopharmacol; 1987; 9(2):141-50. PubMed ID: 3583507
[TBL] [Abstract][Full Text] [Related]
20. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
J Immunother Emphasis Tumor Immunol; ; . PubMed ID: 8280710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
